2016 American Association for Cancer Research (AACR) Annual Meeting

Schedule of DCTD Presentations

Several DCTD staff members will present information at the AACR Annual Meeting in New Orleans, LA from April 16-20, 2016 via the following three presentation categories:

• Oral Presentations
• Poster Presentations
• Meet-the-Expert Presentations

Oral Presentations

Time	Title	Presenter	Location
Saturday, April 16
5:45 PM - 6:00 PM	Careers in Clinical and Translational Cancer Research	Jeffrey A. Moscow, Cancer Therapy Evaluation Program	Carondelet Room, New Orleans Marriott
Sunday, April 17
1:00 PM - 2:00 PM	Funding Opportunities from the Recalcitrant Cancer Research Act of 2012 – Therapeutic development and mechanisms of resistance in SCLC	Suzanne Forry, Developmental Therapeutics Program and Peter Ujhazy, Translational Research Program	Room 352, Morial Convention Center
Monday, April 18
1:00 PM - 3:00 PM	NCI Center for Strategic Scientific Initiatives (CSSI) Programs and Related NCI Opportunities, Tools, and Resources	Paula M. Jacobs, Cancer Imaging Program	Room 352, Morial Convention Center
Tuesday, April 19
10:30 AM - 10:48 AM	Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma		Abstract CT096; Room 391, Morial Convention Center
10:30 AM -12:15 PM	Funding Opportunities for Cancer Research at Multiple NIH Institutes and Centers with NIH Experts	Julia T. Arnold, Translational Research Program	Room 352, Morial Convention Center
12:30 PM - 2:15 PM	Technology Transfer and Intellectual Property: Financial and Career Opportunities for Researchers	Jason V. Cristofaro, Office of the Director	Room 352, Morial Convention Center

Poster Presentations

Time	Title	Location
Sunday, April 17
1:00 PM - 5:00 PM	Building better cell models for screening oncology compounds	Abstract 605; Section 28; Poster Board 6
1:00 PM - 5:00 PM	Similar 3D pharmacodynamic (3D-PD) responses of human tumor spheroids and xenografts to topoisomerase 1 inhibitor-induced DNA damage	Abstract 606; Section 28; Poster Board 7
1:00 PM - 5:00 PM	CellMiner, a systems pharmacological web-application for the NCI-60 cancerous cell-lines: Updates, data integration, and translationally relevant results	Abstract 75; Section 3; Poster Board 15
5:30 PM - 5:45 PM	Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP#7870)	Abstract CT015 Room 291, Morial Convention Center
Monday, April 18
8:00 AM - 12:00 PM	New NCI experimental therapeutics program (NExT) small molecule libraries for academic investigator hts projects	Abstract 1350; Section 20; Poster Board 9
8:00 AM - 12:00 PM	Impact of biospecimen pre-analytical factors on molecular analysis	Abstract 1377; Section 21; Poster Board 8
8:00 AM -12:00 PM	The program for cancer detection, diagnosis, and treatment technologies for global health: Translating affordable, minimally invasive point-of-care technologies to less-resourced settings	Abstract 1428; Section 23; Poster Board 4
1:00 PM - 5:00 PM	Late-Breaking Research: Tumor Biology 2 The genetic landscape of Wilms tumor	Abstract LB-180; Section 11
1:00 PM - 5:00 PM	NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancer	Abstract LB-216; Section 12
Tuesday, April 19
1:00 PM - 5:00 PM	NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis	Abstract CT101; Section 13
Wednesday, April 20
8:00 AM -12:00 PM	Selective inhibition of DNA methyltransferases and efficacy of novel DNMT inhibitors in leukemia xenografts	Abstract 4722; Section 17; Poster Board 3
8:00 AM -12:00 PM	Normal tissue and data resources for cancer research from the GTEx program	Abstract 4500; Section 5; Poster Board 14
8:00 AM -12:00 PM	The National Cancer Institute's biospecimen research database: A community resource for improving specimen quality	Abstract 5264; Section 37; Poster Board 1
8:00 AM -12:00 PM	Determinants of response to temozolomide in an exceptionally sensitive patient derived model	Abstract 5178; Section 33; Poster Board 4

Meet-the-Expert Presentations

NCI Exhibit Booth # 1012

Time	Topic	Presenter
Sunday, April 17
2:15-2:45pm	Specialized Programs of Research Excellence (SPOREs): A funding mechanism for translational research at the National Cancer Institute	Steven Nothwehr, PhD
3:00-3:30pm	NCI Exceptional Responders Initiative	Barbara Conley, MD
Monday, April 18
1:15-1:45pm	NCI’s Experimental Therapeutics Clinical Trials Network	Jeffrey Moscow, MD
3:30-4:00pm	Immune Checkpoint Inhibitors in Cancer Therapy	Elad Sharon, MD, MPH
4:15-4:45pm	NCI-Supported Biospecimen Resources & Funding Opportunities for Cancer Research	Aniruddha Ganguly, PhD
Tuesday, April 19
11:45am-12:15pm	Progress and Opportunities in Biospecimen Science	Helen Moore, PhD
2:00-2:30pm	Small Cell Lung Cancer Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns with Gene and microRNA Expression	Beverly Teicher, PhD
2:45-3:15pm	Assay Validation For High Quality Markers For NCI-Supported Clinical Trials: A Cancer Diagnosis Program Funding Opportunity	Tawnya McKee, PhD

DCTD Kiosk Activity: NCI Exhibit Booth # 1012

• Kiosk will be attended by DCTD program Staff.
• Activities include interacting with prospective and present grantees, distributing program information and funding opportunities, and providing guidance to prepare grant applications.

Kiosk hours are listed below:

Sunday, April 17

1:00 pm – 5:00 pm

Monday, April 18

9:00 am – 5:00 pm

Tuesday, April 19

9:00 am – 5:00 pm

Wednesday, April 20

9:00 am – 12:00 pm